Research Article

Risk Factors for Mortality in Patients with Septic Acute Kidney Injury in Intensive Care Units in Beijing, China: A Multicenter Prospective Observational Study

Xin Wang,1,2 Li Jiang,1 Ying Wen,1 Mei-Ping Wang,1 Wei Li,3 Zhi-Qiang Li,4 and Xiu-Ming Xi1

1 Department of Critical Care Medicine, Fu Xing Hospital, Capital Medical University, Beijing 100038, China
2 Department of Surgical Intensive Care Units, Hepatobiliary Surgery and Liver Transplant Center, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China
3 Center for Infectious Diseases, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China
4 Department of Critical Care Medicine, Hospital affiliated to Hebei United University, Tangshan 06300, China

Correspondence should be addressed to Xiu-Ming Xi; xxm2947@sina.com

Received 12 May 2014; Accepted 14 June 2014; Published 7 July 2014

Academic Editor: Mingyue Zheng

Copyright © 2014 Xin Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To discover risk factors for mortality of patients with septic AKI in ICU via a multicenter study. Background. Septic AKI is a serious threat to patients in ICU, but there are a few clinical studies focusing on this. Methods. This was a prospective, observational, and multicenter study conducted in 30 ICUs of 28 major hospitals in Beijing. 3,107 patients were admitted consecutively, among which 361 patients were with septic AKI. Patient clinical data were recorded daily for 10 days after admission. Kidney Disease: Improving Global Outcomes (KDIGO) criteria were used to define and stage AKI. Of the involved patients, 201 survived and 160 died. Results. The rate of septic AKI was 11.6%. Twenty-one risk factors were found, and six independent risk factors were identified: age, APACHE II score, duration of mechanical ventilation, duration of MAP < 65 mmHg, time until RRT started, and progressive KDIGO stage. Admission KDIGO stages were not associated with mortality, while worst KDIGO stages were. Only progressive KDIGO stage was an independent risk factor. Conclusions. Six independent risk factors for mortality for septic AKI were identified. Progressive KDIGO stage is better than admission or the worst KDIGO for prediction of mortality. This trial is registered with ChiCTR-ONC-11001875.

1. Introduction

Globally, the incidence of acute kidney injury (AKI) has increased steadily in recent years [1–4]. AKI is commonly seen in critically ill patients in ICU [5, 6] and contributes to the failure of other organs and systems in such patients [7]. The duration of AKI can be used to predict disease severity and outcome [8] although even transient AKI is linked to increased mortality [9]. The risk of death in AKI patients shows an incremental increase corresponding to disease stage [10]. Known risk factors of AKI include sepsis, critical illness, circulatory shock, burns, trauma, cardiac surgery, chronic diseases (heart, lung, and liver), major noncardiac surgery, and nephrotoxic drugs [11].

The cause of AKI in critically ill patients is usually multifactorial; however, sepsis is one of the leading causes of AKI, contributing to more than half of all reported cases [12–14]. The mechanism of sepsis-induced AKI is a complex combination of factors such as vascular and glomerular thrombotic processes, inflammation, and shock and is distinct from nonseptic AKI [15–18]. Thus, the clinical presentation, outcome, and responses to therapy may differ between septic and nonseptic AKI. Septic AKI is coupled with a significantly increased risk for hospital death, even after adjustment for relevant covariates [19]. However, only a limited number of clinical studies focusing on septic AKI in ICUs have been reported [19–23]. Thorough investigation is urgently required to reveal the epidemiology, pathophysiology, clinical features,
and, more importantly, effective therapeutic measures for this disorder to reduce its high mortality.

This study aimed to identify risk factors for mortality in ICU patients with septic AKI and to evaluate the use of the KDIGO staging system for the prediction of prognosis in this group of patients, via a multicenter clinical study.

2. Material and Methods

This observational multicenter study was a retrospective analysis of prospectively collected data from patients in 30 ICUs of 28 major hospitals in Beijing between March 1 and August 31, 2012, as a part of the BAKIT (Beijing AKI Trail) study. Study subjects included all adult patients (age ≥18 years) admitted consecutively to the ICU and who received care in the ICU for at least 24 hours. Only the initial ICU admission was considered in this study. The following patients were excluded from the study: patients with preexisting end-stage chronic kidney disease, those already on RRT before admission to ICU, and those who had received kidney transplantation in the previous 3 months.

This study was approved by the Institutional Review Board of the Ethics Committee of the lead study center (Fu Xing Hospital, Capital Medical University, China), which waived the requirement for informed consent for this observational survey. Patient records/information were anonymized and deidentified prior to analysis.

2.1. Case Identification. Nine hundred and seventeen patients diagnosed with sepsis were identified [24]. AKI severity was classified according to the KDIGO guidelines (Kidney Disease: Improving Global Outcomes) [11], as follows: AKI is defined by an increase in serum creatinine (SCr) by ≥26.5 µmol/L within 48 hours or an increase of SCr of ≥1.5 times over baseline (which is known or presumed within the prior 7 days) or urine volume <0.5 mL/kg/h for 6 hours. AKI is staged for severity (3 stages) based on the changes in SCr and urine volume. Patients were staged according to SCr or urine output or both, with the criteria leading to the highest stage being used. Baseline SCr was the last value within the preceding year. For patients without these values or without renal failure, baseline SCr was estimated by the Modification of Diet in Renal Disease (MDRD) equation [25], assuming a glomerular filtration rate of 75 mL/min/1.73 m² [6]. For patients with chronic renal failure but not on dialysis, the initial SCr value on admission was used as the baseline value [6].

2.2. Data Collection. A uniform case report form (CRF) was used to collect data. Standard demographic, clinical, and laboratory data collected in the ICU included age, sex, dates and source of admission, BMI, blood pressure, duration of ICU stay, comorbidities, nonrenal organ failures, daily fluid input and output, and serum creatinine. The use of interventions, such as RRT, mechanical ventilation, loop diuretic therapy, and vasoactive agents, was also recorded.

Severity of illness was assessed by the Acute Physiology and Chronic Health Evaluation (APACHE) II score and Sequential Organ Failure Assessment (SOFA) scores, which were calculated based on the worst variables recorded during the first 24 hours after ICU admission to evaluate patient status [26, 27]. AKI severity was evaluated by KDIGO staging. Preexisting comorbidities were diagnosed based on International Classification of Diseases (ICD-10). For all patients included in the study, a thorough follow-up was conducted for the first 10 days after ICU admission. Patient status, laboratory data, interventions, and KDIGO stages were recorded daily. End points of this study included death or being transferred out of the ICU.

2.3. Definitions. Septic AKI was defined as sepsis-associated AKI [20, 28, 29], which meant that sepsis was associated with development and progression of AKI, so the patients (n = 235) with sepsis whose sepsis was not associated with AKI were excluded (Figure 1). We defined sepsis according to the American College of Chest Physicians and the Society of Critical Care Medicine (ACCP/SCCM) consensus [24, 30]. Based on this consensus, SIRS is defined as temperature >38°C.
or <36°C, heart rate >90/min, respiratory rate >20/min or PaCO2 <<32 mmHg, and white blood cell count >12,000/mm³ or <4,000/mm³ or with >10% bands. Sepsis was defined as a condition in which the patient met the criteria for SIRS and presented with either a documented or suspected infection. Admission KDIGO refers to the KDIGO stage on the first day of admission, while worst KDIGO refers to the worst KDIGO stage reached by a patient during their ICU stay. ICU-acquired AKI was defined as the development of AKI at 24 hours or more after admission, with the absence of AKI prior to admission. Progressive AKI was defined as patients reaching a higher KDIGO stage compared with the admission KDIGO stage at any time during their ICU stay. Vasoactive agents used in this study included epinephrine, norepinephrine, dopamine, and dobutamine. Large-dose vasopressor was defined as norepinephrine or epinephrine administered at a dose of >0.1 µg/kg/min, or dopamine or dobutamine administered at a dose of >15 µg/kg/min, or any two or more drugs in combination. Hospital acquired infection was defined as the development of an infection within 48 hours after hospital admission, which was not presented or incubating at the time of admission to the hospital.

2.4. Statistical Analysis. SPSS software (version 15.0) was used for data analysis. All variables were tested for normal distribution using the Kolmogorov-Smirnov test. Normally or near normally distributed variables are presented as means and SD, nonnormally distributed continuous data are presented as medians and interquartile ranges (IQR). Student's t-test was used for analysis of continuous variables. Mann-Whitney U test was used for nonnormally distributed variables. Categorical variables were compared with the chi-square test or Fisher's exact test. A 2-tailed P <0.05 was considered statistically significant. Logistic regression was used to analyze risk factors for mortality. All variables with a P value <0.001 were included in the multivariate model. Backward selection based on the likelihood ratio test was used to select the final multivariate model for risk factors of mortality.

3. Results

3.1. Patient Characteristics. During the 6-month study period, a total of 3,107 patients were admitted to the 30 ICUs involved in this study, of which 29.5% (917/3,107) were diagnosed with sepsis. Of these patients, 39.4% (361/917) of patients were diagnosed with septic AKI; among which 55% (201/361) of patients survived and 44.4% (160/361) died. The rate of septic AKI among all subjects was 11.6% (361/3,107) (Figure 1). The average age was 70.54 ± 16.04 years, and 64.0% were male. Average BMI was 23.16 ± 3.82 and 37.7% were identified as hospital acquired infections. The average first 24 h APPACHE II score in the ICU was 23.59 ± 7.87, and the first 24 h SOFA score was 10.49 ± 5.40. The age, sex, BMI, hospital acquired infection, ways of admission, duration in ICU, nonrenal organ failure, comorbid diseases, and first 24 h APACHE II and SOFA scores in the ICU were compared between survivors and nonsurvivors. The age (P < 0.001), hospital acquired infection (P = 0.001), surgical admission (P = 0.004) and emergency admission (P = 0.003), systolic heart failure (P = 0.007), malignancy (P = 0.031), heart function level IV (P = 0.021), first 24 h APACHE II score (P < 0.001), and SOFA score (P < 0.001) in the ICU were associated with mortality (Table 1).

3.2. Disease Progression in the ICU. Disease progression was observed consecutively in the first 10 days after admission to the ICU in this study, and key interventions and parameters were recorded and analyzed. In total, 78.9% of septic AKI patients were on mechanical ventilation, 35.5% of patients needed RRT. Data on mechanical ventilation, fluid balance, hemodynamic data, and duration of vasoactive agent administration, loop diuretic therapy, and RRT were compared between survivors and nonsurvivors. Mechanical ventilation (P < 0.001) and its duration (P < 0.001), daily fluid balance (P = 0.001), duration of MAP <65 mmHg (P < 0.001), days on vasopressors (P < 0.001) and high-dose vasopressors (P < 0.001), RRT (P = 0.007), and time interval between ICU admission and RRT initiation (P < 0.001) were associated with patient outcomes (Table 2).

3.3. KDIGO Stages and Patient Outcome. During the first 10 days of ICU care, renal function of the patients was evaluated once a day according to KDIGO stage in this study. A flowchart of the progression of AKI in the ICU measured by KDIGO stages is shown in Figure 2. On admission, 27.7% (100/361) of all patients were at KDIGO stage 0, 29.9% (108/361) were at stage 1, 17.2% (62/361) were at stage 2, and 25.2% (91/361) were at stage 3. For the worst KDIGO stages, none of the patients were at stage 0, 20.8% (75/361) of patients were at stage 1, 25.5% (92/361) were at stage 2, and 53.7% (194/361) were at stage 3. Admission KDIGO stages were not linked to patient outcome, while the worst KDIGO stages were. According to our data, patients categorized into KDIGO stages 1, 2, and 3 by the worst KDIGO stages were strongly associated with patient outcome (P < 0.001, P = 0.038, and P < 0.001, resp.). ICU-acquired AKI was not linked to disease outcome (P = 0.110). Progressive AKI was associated with mortality (P < 0.001) (Table 3). Mortality rates for patients at different admission and the worst KDIGO stages are shown in Figure 3.

3.4. Risk Factors for Mortality. To identify possible risk factors for mortality in ICU patients with septic AKI, univariate analysis was performed for all the tested factors with a P value <0.05. Multivariate regression analysis was performed for all parameters with a P value <0.001 in the univariate analysis. Six independent risk factors were identified: age (OR = 1.025, 95% CI (1.007–1.042), P = 0.005), APACHE II score (first 24 h in ICU) (OR = 1.072, 95% CI (1.037–1.109), P < 0.001), duration of mechanical ventilation (OR = 1.080, 95% CI (1.008–1.158), P = 0.03), duration of MAP <65 mmHg (OR = 1.149, 95% CI (1.032–1.279), P = 0.011), time interval between ICU admission and RRT initiation (OR = 1.238, 95% CI (1.115–1.374), P < 0.001), and progressive KDIGO stage (OR = 3.374, 95% CI (1.918–5.933), P < 0.001) (Table 4).
### Table 1: Patient characteristics.

|                          | Survivors (n = 201) | Nonsurvivors (n = 160) | P value |
|--------------------------|---------------------|------------------------|---------|
| Age (years; median [IQR])| 72 (56–81)          | 78 (67–83)             | <0.001  |
| Gender (male) n (%)      | 131/201 (65.17%)    | 100/160 (62.50%)       | 0.264   |
| BMI (mean ± SD)          | 23.50 ± 3.56        | 22.73 ± 4.09           | 0.058   |
| Hospital acquired infection n (%) | 61/201 (30.35%) | 75/160 (46.88%)       | 0.001   |
| Admission, n (%)         |                     |                        |         |
| Surgical admission       | 38/201 (18.91%)     | 14/160 (8.75%)         | 0.004   |
| Emergency                | 83/201 (41.29%)     | 56/160 (35%)           | 0.003   |
| Duration in ICU          |                     |                        |         |
| Days in ICU (days; median [IQR]) | 9 (5–16)       | 9 (5–19)               | 0.737   |
| Nonrenal organ failure, n (%) |      |                        |         |
| Respiratory failure      | 124/201 (61.69%)    | 112/160 (70%)          | 0.099   |
| Systolic heart failure   | 11/201 (5.47%)      | 22/160 (13.75%)        | 0.007   |
| Hypovolemia shock        | 17/201 (8.46%)      | 19/160 (11.88%)        | 0.282   |
| Septic shock             | 80/201 (39.8%)      | 68/160 (42.50%)        | 0.604   |
| DIC                      | 13/201 (6.47%)      | 8/160 (5.00%)          | 0.554   |
| Hepatic failure          | 12/201 (5.97%)      | 8/160 (5.00%)          | 0.500   |
| MODS (nonrenal)          | 62/201 (30.85%)     | 65/160 (40.63%)        | 0.051   |
| Comorbid disease, n (%)  |                     |                        |         |
| Malignancy               | 34/201 (16.92%)     | 43/160 (26.88%)        | 0.031   |
| Hypertension/CHD         | 108/201 (53.73%)    | 94/160 (58.75%)        | 0.340   |
| Diabetes mellitus        | 48/201 (23.88%)     | 33/160 (20.63%)        | 0.461   |
| CKD without renal failure| 11/201 (5.47%)      | 4/160 (2.50%)          | 0.160   |
| CKD with renal failure   | 19/201 (9.45%)      | 21/160 (13.13%)        | 0.269   |
| Immunosuppression        | 9/201 (4.48%)       | 7/160 (4.38%)          | 0.586   |
| Organ transplant         | 5/201 (2.49%)       | 2/160 (1.25%)          | 0.47    |
| Heart function level IV  | 14/201 (6.97%)      | 23/160 (14.36%)        | 0.021   |
| APACHE II score, first 24 h in ICU (mean ± SD) | 21.41 ± 7.74 | 26.32 ± 7.15 | <0.001 |
| SOFA score, first 24 h in ICU (mean ± SD) | 9.42 ± 5.33 | 11.83 ± 5.21 | <0.001 |

BMI: body mass index, RRT: renal replacement therapy, CKD: chronic kidney disease, ICU: intensive care unit, DIC: disseminated intravascular coagulation, MODS: multiple organ dysfunction syndrome, CHD: chronic heart disease, SOFA: sequential organ failure assessment, APACHE: acute physiology and chronic health evaluation.

### Table 2: Data on disease progression in the first 10 days after admission to ICU.

|                              | Survivors (n = 201) | Nonsurvivors (n = 160) | P value |
|------------------------------|---------------------|------------------------|---------|
| Mechanical ventilation       |                     |                        |         |
| Patients on mechanical ventilation n (%) | 145/201 (72.14%) | 140/160 (87.5%) | <0.001  |
| Duration on mechanical ventilation (days; median [IQR]) | 3 (0–7) | 6 (3–10) | <0.001  |
| Fluid management             |                     |                        |         |
| Duration for positive fluid balance (days; median [IQR]) | 5 (3–7) | 5 (3–7) | 0.583   |
| Daily fluid balance (mL/24 h) | 654 ± 794        | 982 ± 1024             | 0.001   |
| Hemodynamic data             |                     |                        |         |
| Duration for MAP < 65 mmHg (days; mean ± SD) | 1.50 ± 1.98 | 2.42 ± 2.60 | <0.001  |
| Vasoactive agents            |                     |                        |         |
| Days on vasopressors (median [IQR]) | 1 (0–4) | 3 (2–6) | <0.001  |
| Days on large-dose vasopressor (median [IQR]) | 0 (0–3) | 3 (0–5) | <0.001  |
| Loop diuretic therapy (days) (median [IQR]) | 2 (0–6) | 2 (1–5) | 0.693   |
| RRT                          |                     |                        |         |
| Need for RRT n (%)           | 59/201 (29.35%)     | 69/160 (43.13%)        | 0.007   |
| Duration of RRT (days; median [IQR]) | 0 (0–3) | 0 (0–2) | 0.065   |
| Time interval between admission and RRT initiation (days; median [IQR]) | 0 (0–1) | 0 (0–4) | <0.001  |

RRT: renal replacement therapy; MAP: mean arterial pressure.
4. Discussion

In this study, we investigated possible risk factors for mortality in critically ill patients with septic AKI via a large, multicenter, and observational study involving 30 ICUs. A total of 21 risk factors and six independent risk factors were identified in a thorough statistical analysis of comparisons between survivors and nonsurvivors among critically ill patients with septic AKI.

Our data showed low mortality among septic AKI patients admitted from the surgical or emergency departments (Table 1). Many surgical patients in the ICU were admitted for routine postoperative care after major operations and were associated with a very low mortality rate. Many patients admitted from emergency departments were in acute conditions, and, after timely interventions in ICU, most of them recovered well.

Mechanical ventilation is a common and important intervention in the ICU. In our study, the use of mechanical ventilation was correlated with increased mortality ($P < 0.001$). This is possibly due to the common complications of mechanical ventilation, such as worsening inflammatory responses, altered systemic hemodynamics, and elevated intrathoracic and intra-abdominal pressure, all of which are...
Table 4: Regression analysis of risk factors for mortality in ICU.

| Risk Factor                              | Univariate Analysis | Multivariate Analysis |
|------------------------------------------|---------------------|-----------------------|
|                                          | OR (95% CI)         | P value               |
| Age (years)                              | 1.026 (1.012–1.041) | <0.001                |
| Hospital acquired infection              | 2.025 (1.314–3.120) | 0.001                 |
| Nonrenal organ failure                   |                     |                       |
| Systolic heart failure                   | 2.754 (1.293–5.866) | 0.009                 |
| Comorbid disease                         |                     |                       |
| Malignancy                               | 1.748 (1.050–2.911) | 0.032                 |
| Heart function IV                        | 2.242 (1.144–4.516) | 0.024                 |
| APACHE II score                          | 1.092 (1.059–1.129) | <0.001                |
| SOFA score                               | 1.090 (1.046–1.135) | <0.001                |
| Mechanical ventilation                   |                     |                       |
| Patients on mechanical ventilation       | 2.703 (1.543–4.737) | 0.001                 |
| Duration on mechanical ventilation       | 1.136 (1.071–1.206) | <0.001                |
| Fluid management                          |                     |                       |
| Daily fluid balance (mL/24 h)            | 1.000 (1.000–1.001) | 0.001                 |
| Hemodynamic data                         |                     |                       |
| Duration for MAP < 65 mmHg               | 1.195 (1.083–1.319) | <0.001                |
| Vasoactive agents                        |                     |                       |
| Vasopressors                             | 1.211 (1.126–1.302) | <0.001                |
| RRT                                      |                     |                       |
| Need for RRT n (%)                       | 1.825 (1.180–2.822) | 0.007                 |
| Time until RRT started (days)            | 1.261 (1.146–1.388) | <0.001                |
| Worst KDIGO                              |                     |                       |
| Stage 1 n (%)                            | 0.379 (0.216–0.665) | 0.001                 |
| Stage 2 n (%)                            | 0.625 (0.384–1.019) | 0.060                 |
| Stage 3 n (%)                            | 2.645 (1.718–4.073) | <0.001                |
| Progress KDIGO class                     |                     |                       |
| Progressive AKI                          | 3.341 (2.039–5.475) | <0.001                |

OR: odd ratio; APACHE II score, first 24 h in ICU; SOFA score, first 24 h in ICU.

involved in the development of AKI [31, 32]. In further analysis, we found that the duration of mechanical ventilation was an independent risk factor for mortality in patients with septic AKI, which may be due to the occurrence of ventilator-associated pneumonia (VAP), one of the leading causes of death in mechanically ventilated patients [33]. Compared with septic AKI survivors, nonsurvivors had greater hemodynamic instability: suffering from longer duration of hypotension (MAP < 65 mmHg), receiving more fluid and vasopressor even large-dose vasopressor [34]. Lopes and colleagues discovered that extensive use of vasopressors was found in patients with severe AKI and associated with poor prognosis [35]. This is consistent with our data in Table 2.

In critically ill patients, it has been reported that positive fluid balance impaired cardiac function, led to lung injury, and may contribute to the development of AKI, which, in turn, increase mortality [36]. In patients with sepsis, prior report has shown that cumulative positive fluid balance was associated with increased mortality (odds ratio = 1.2) after adjustment for disease severity [37]. In our study, we came to the same conclusion in septic AKI patients (Table 2).

So, it seems that septic AKI patients with a long duration of low MAP required more vasoactive drug use and positive fluid balance, which implied high risk of shock and poor outcome.

RRT is one of the main approaches to the management of AKI. Recently, a multicenter study shown that in the nonsurvival with septic AKI, proportion of receiving RRT was significantly higher than that in the survival [29]. Our findings are consistent with this study: compared with the septic AKI patients who survived, proportion of receiving RRT was significantly higher in who died (43.13% versus 29.35%, \( P = 0.007 \)). Furthermore, we found that there was no significant difference in duration of RRT between survivors and nonsurvivors with septic AKI (\( P = 0.065 \)).

In addition, it is interesting that the time interval between ICU admission and RRT initiation was significantly longer in the patient who died. Moreover, by multivariate analysis, this delay in initiation of RRT was an independent risk factor for
mortality (Tables 2 and 4). A large multicenter study about septic AKI came to the same conclusion that the time between ICU admission and start of RRT was significantly longer in the patients with septic AKI and this delay in initiation of RRT was independently associated with hospital mortality [20]. The right time to start RRT is still a topic of debate [38]. Experts recommend beginning RRT earlier, particularly in sepsis where AKI is known to be rapidly progressive [38]. A meta-analysis about timing of RRT clearly favored to begin RRT at early time [39]. In our study, the delay in initiation of RRT associated with mortality might be partly explained that progression of AKI in ICU was also an independent risk factor for mortality (Table 4). Patients with septic AKI who are with progression of AKI in ICU might receive RRT later after ICU admission than patients without progression of AKI. In brief, this observation showed that starting RRT timely is a key factor to reduce the high mortality of patients with septic AKI.

Many previous studies have evaluated AKI in critically ill patients by using the RIFLE classification [40] or AKIN criteria [41] and reported it to be associated with risk for mortality [6, 41–44]. KDIGO criteria is a new scaling system for AKI severity [11] and has been proven to be of prognostic significance [45, 46]. Some studies have indicated that KDIGO classification is better than RIFLE in terms of outcome prediction in certain circumstances [46]. Here we aimed to use KDIGO classification to evaluate critically ill patients with septic AKI.

Patients with poor admission KDIGO stages can be effectively treated by stage-based management such as hemodynamic monitoring, ensuring volume status and perfusion pressure, monitoring serum creatinine and urine output [11] and early goal-directed therapy (EGDT) [47]. However, later development of AKI progression to a higher stage of AKI after ICU admission implies poor prognosis [21, 48].

It is interesting that in the worst KDIGO stages (Table 3), we found that only KDIGO stage 3 was associated with a high mortality, while survivors had a greater incidence of KDIGO stages 1 and 2. A multicenter study about septic AKI in Finnish came to the same conclusion; they found that after adjusting for covariates, the worst KDIGO stage 3 was associated with increased risk for 90-day mortality, but stages 1 and 2 were not [29]. It can be explained that although receiving active treatment in ICU, if the severity of septic AKI still progressed to KDIGO stage 3, the mortality would increase significantly. If the worst KDIGO stage of septic AKI only reached stages 1 or 2 in ICU, it would imply a good outcome.

Although the worst KDIGO stages were associated with mortality, they were not independent risk factors, while progressive KDIGO stage was found to be an independent risk factor associated with poor prognosis (Table 4). This is consistent with the results of other septic AKI studies, where progression of AKI has important prognostic implications [21, 49]. This result indicated the necessity of monitoring changes in KDIGO stages when AKI occurred in patients with sepsis in the ICU. On the other hand, ICU-acquired AKI was not a risk factor for mortality in our study (Table 4) but was an independent risk factor for 28-day mortality in a RIFLE-based study [21]. There were two differences between this study and ours. Firstly, its subject was patients with severe sepsis and septic shock, while the subject of our study was patients with septic AKI. Secondly, this study was a single center study targeting patients from medical ICU, thus limiting the applicability to more heterogeneous populations. In contrast, our study was a multicenter study involving various types of ICUs.

Our study has several limitations. First, baseline creatinine concentration was not measured for all patients; therefore, in such cases this value was estimated using the MDRD equation. Second, use of antibiotics is critical for management of sepsis but was not observed and involved in this study, because this was a substudy of the BAKIT (Beijing AKI Trail) study.

Through a consecutively thorough follow-up for 10 days after ICU admission, we found that the independent risk factors for mortality, except age and APACHE II score, the other four factors were all dynamic observational ones, such as duration (MAP, mechanical ventilation), time interval between admission, and RRT initiation and progression (KDIGO stage), while static factors such as need for RRT and the worst KDIGO stages were not independent risk factors. It suggests that we need to consecutively monitor the conditions of septic AKI patients. Currently, most of
observational studies for septic AKI collected clinical data for only one day [19, 28]; therefore the value of these data for predicting the prognostic for septic AKI is limited.

5. Conclusion

In summary, via a multicenter observational study, we evaluated the use of KDIGO stages on predicting patient outcome, found twenty-one risk factors such as age, hospital acquired infection, systolic heart failure, and mechanical ventilation, and identified six independent risk factors for mortality in ICU patients with septic AKI, which may help make early and accurate diagnosis and adopting preventive and therapeutic interventions that could reduce mortality rates in patients with septic AKI.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was supported by a Grant from the Beijing Municipal Science & Technology Commission (BSTC), a government fund used to improve healthcare quality (no. D101100050010058). It offered financial support for data collection. The authors thank all members of the Beijing Acute Kidney Injury Trial (BAKIT) work group in participating for database management. The Beijing Acute Kidney Injury Trial (BAKIT) workgroup: Bin Du, Medical Intensive Care Unit, Peking Union Medical College Hospital, Beijing, China; Yuan Xu, Department of Critical Care Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Jianxin Zhou, Department of Critical Care Medicine, Beijing Tiantan Hospital affiliated to Capital Medical University, Beijing, China; Ang Li, Department of Critical Care Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, China; Jingyuan Liu, Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China; Wenxiong Li, Surgical Intensive Care Unit, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China; Wenjin Chen, Neurological intensive care unit, Xuanwu Hospital, Capital Medical University, Beijing, China; JinguoJia, Surgical Intensive Care Unit, Xuanwu Hospital, Capital Medical University, Beijing, China; Penglin Ma, Department of Critical Care Medicine, The 309th Hospital of Chinese People’s Liberation Army, Beijing, China; Xi Zhu, Department of Critical Care Medicine, Peking University Third Hospital, Beijing, China; Wei Chen, Department of Critical Care Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China; Dongxin Wang, Department of Critical Care Medicine, Peking University First Hospital, Beijing, China; Youzhong An, Department of Critical Care Medicine, Peking University People's Hospital, Beijing, China; Qingyuan Zhan, Department of Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China; Gang Li, Department of Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China; Haitao Zhang, Surgical Intensive Care Unit, Fuwai Hospital, China Academy of Medical Science and Peking Union Medical College, Beijing, China; Bo Ning, Department of Critical Care Medicine, Air Force General Hospital of Chinese People’s Liberation Army, Beijing, China; Zhongjie He, Department of Critical Care Medicine, The First Affiliated Hospital of General Hospital of People’s Liberation Army, Beijing, China; Zhicheng Zhang, Department of Critical Care Medicine, Navy General Hospital, Beijing, China; Yaxiong Sun, Department of Critical Care Medicine, The Luhe Teaching Hospital of the Capital Medical University, Beijing, China; ShijieJia, Surgical Intensive Care Unit, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Yalin Liu, Surgical Intensive Care Unit, Beijing Hospital, Capital Medical University, Beijing, China; Rui Cheng, Department of Critical Care Medicine, General Hospital of Armed Police Forces, Beijing, China; Qing Song, Department of Critical Care Medicine, The General Hospital of People’s Liberation Army, Beijing, China; Jinning Liu, Surgical Intensive Care Unit, Department of Hepatobiliary Surgery and Liver Transplant Center, Beijing YouAn Hospital, Capital Medical University, Beijing, China; Yangong Chao, Department of Critical Care Medicine, Hua Xin Hospital, First Hospital of Tsinghua University, Beijing, China; Huizhen Li, Department of Critical Care Medicine, Beijing Shunyi Hospital of China Medical University, Beijing, China; Li Feng, Department of Critical Care Medicine, Beijing Geriatric Hospital, Beijing, China; Ruochun Shi, Department of Critical Care Medicine, Beijing No. 6 Hospital, Beijing, China; Department of Critical Care Medicine, Fuxing Hospital, Capital Medical University, Beijing, China; Ying Wen, Meiping Wang, Bo Zhu, Qi Jiang, Yujie Deng, Yan Sun, Peng Wang, Yanyan Yin, Xin Zhang, Li Zhang, Zhen Zhao, Ying Wang, RanLou, and Jing Wang.

References

[1] T. Z. Ali, I. Khan, W. Simpson et al., “Incidence and outcomes in acute kidney injury: a comprehensive population-based study,” Journal of the American Society of Nephrology, vol. 18, no. 4, pp. 1292–1298, 2007.
[2] S. S. Waikar, G. C. Curhan, R. Wald, E. P. McCarthy, and G. M. Chertow, “Declining mortality in patients with acute renal failure, 1988 to 2002,” Journal of the American Society of Nephrology, vol. 17, no. 4, pp. 1143–1150, 2006.
[3] J. L. Xue, F. Daniels, R. A. Star et al., “Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001,” Journal of the American Society of Nephrology, vol. 17, no. 4, pp. 1135–1142, 2006.
[4] N. H. Lameire, A. Bagga, D. Cruz et al., “Acute kidney injury: an increasing global concern,” The Lancet, vol. 382, no. 9887, pp. 170–179, 2013.
[5] S. Uchino, J. A. Kellum, R. Bellomo et al., “Acute renal failure in critically ill patients: a multinational, multicenter study,” The Journal of the American Medical Association, vol. 294, no. 7, pp. 813–818, 2005.
[6] E. A. J. Hoste, G. Clermont, A. Kersten et al., “RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis,” Critical Care, vol. 10, no. 3, article R73, 2006.
[7] M. E. Grams and H. Rabb, “The distant organ effects of acute kidney injury,” *Kidney International*, vol. 81, no. 10, pp. 942–948, 2012.

[8] J. R. Brown, R. S. Kramer, S. G. Coca, and C. R. Parikh, “Duration of acute kidney injury impacts long-term survival after cardiac surgery,” *The Annals of Thoracic Surgery*, vol. 90, no. 4, pp. 1142–1148, 2010.

[9] M. Nejat, J. W. Pickering, P. Devarajan et al., “Some biomarkers of acute kidney injury are increased in pre-renal acute injury,” *Kidney International*, vol. 81, no. 12, pp. 1254–1262, 2012.

[10] M. Joannidis, B. Metnitz, P. Bauer et al., “Acute kidney injury in critically ill patients classified by AKIN versus RIFLE using the SAPS 3 database,” *Intensive Care Medicine*, vol. 35, no. 10, pp. 1692–1700, 2009.

[11] (KDIGO) KDIGO, “Clinical practice guideline for acute kidney injury,” *Kidney International Supplements*, vol. 2, pp. 124–138, 2012.

[12] D. C. Angus, W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky, “Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care,” *Critical Care Medicine*, vol. 29, no. 7, pp. 1303–1310, 2001.

[13] S. M. Bagshaw, K. B. Laupland, C. J. Doig et al., “Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study,” *Critical Care*, vol. 9, no. 6, pp. R700–R709, 2005.

[14] W. Silvester, R. Bellomo, and L. Cole, “Epidemiology, management, and outcome of severe acute renal failure of critical illness in Australia,” *Critical Care Medicine*, vol. 29, no. 10, pp. 1910–1915, 2001.

[15] R. Jacobs, P. M. Honore, O. Joannes-Boyau et al., “Septic acute kidney injury: the culprit is inflammatory apoptosis rather than ischemic necrosis,” *Blood Purification*, vol. 32, no. 4, pp. 262–265, 2011.

[16] C. Langenberg, L. Wan, M. Egi, C. N. May, and R. Bellomo, “Renal blood flow in experimental septic acute renal failure,” *Kidney International*, vol. 69, no. 11, pp. 1996–2002, 2006.

[17] C. Langenberg, L. Wan, S. M. Bagshaw, M. Egi, C. N. May, and R. Bellomo, “Urinary biochemistry in experimental septic acute renal failure,” *Nephrology Dialysis Transplantation*, vol. 21, no. 12, pp. 3389–3397, 2006.

[18] M. Brenner, G. L. Schaer, D. L. Mallory, A. F. Suffredini, and J. E. Parillo, “Detection of renal blood flow abnormalities in septic and critically ill patients using a newly designed indwelling thermodilution renal vein catheter,” *Chest*, vol. 98, no. 1, pp. 170–179, 1990.

[19] M. Oppert, C. Engel, F.-M. Brunkhorst et al., “Acute renal failure in patients with severe sepsis and septic shock—a significant independent risk factor for mortality: results from the German Prevalence Study,” *Nephrology Dialysis Transplantation*, vol. 23, no. 3, pp. 904–909, 2008.

[20] S. M. Bagshaw, S. Uchino, R. Bellomo et al., “Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes,” *Clinical Journal of the American Society of Nephrology*, vol. 2, no. 3, pp. 431–439, 2007.

[21] W. Y. Kim, J. W. Huh, C.-M. Lim, Y. Koh, and S.-B. Hong, “Analysis of progression in risk, injury, failure, loss, and end-stage renal disease classification on outcome in patients with severe sepsis and septic shock,” *Journal of Critical Care*, vol. 27, no. 1, pp. 104.e1–104.e7, 2012.

[22] M. Plataki, K. Kashani, J. Cabello-Garza et al., “Predictors of acute kidney injury in septic shock patients: an observational cohort study,” *Clinical Journal of the American Society of Nephrology*, vol. 6, no. 7, pp. 1744–1751, 2011.

[23] E. A. J. Hoste, N. H. Lameire, R. C. Vanholder, D. D. Benoit, J. M. A. Decruyenaere, and F. A. Colardyn, “Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome,” *Journal of the American Society of Nephrology*, vol. 14, no. 4, pp. 1022–1030, 2003.

[24] R. C. Bone, R. A. Balk, F. B. Cerra et al., “Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine,” *Chest*, vol. 101, no. 6, pp. 1644–1655, 1992.

[25] A. S. Levey, J. Coresh, E. Balk et al., “National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification,” *Annals of Internal Medicine*, vol. 139, no. 2, pp. 137–147, 2003.

[26] W. A. Knaus, E. A. Draper, D. P. Wagner, and J. E. Zimmerman, “APACHE II: a severity of disease classification system,” *Critical Care Medicine*, vol. 13, no. 10, pp. 818–829, 1985.

[27] J.-L. Vincent, R. Moreno, J. Takala et al., “The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure,” *Intensive Care Medicine*, vol. 22, no. 7, pp. 707–710, 1996.

[28] S. M. Bagshaw, C. George, and R. Bellomo, “Early acute kidney injury and sepsis: a multicentre evaluation,” *Critical Care*, vol. 12, no. 2, article R47, 2008.

[29] M. Poukkana, S. T. Vaara, V. Pettilä et al., “Acute kidney injury in patients with severe sepsis in finnish intensive care units,” *Acta Anaesthesiologica Scandinavica*, vol. 57, no. 7, pp. 863–872, 2013.

[30] “American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis,” *Critical Care Medicine*, vol. 20, no. 6, pp. 864–874, 1992.

[31] J. L. Koyner and P. T. Murray, “Mechanical ventilation and lung-kidney interactions,” *Clinical Journal of the American Society of Nephrology*, vol. 3, no. 2, pp. 562–570, 2008.

[32] A. S. Awad, M. Rouse, L. Huang et al., “Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injury,” *Kidney International*, vol. 75, no. 7, pp. 689–698, 2009.

[33] A. H. Choudhuri, “Ventilator-Associated Pneumonia: when to hold the breath?” *International Journal of Critical Infrastructure Protection*, vol. 3, no. 3, pp. 169–174, 2013.

[34] S. M. Bagshaw, S. Lapinsky, S. Dial et al., “Acute kidney injury in sepsis: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy,” *Intensive Care Medicine*, vol. 35, no. 5, pp. 871–881, 2009.

[35] J. A. Lopes, S. Jorge, C. Resina et al., “Acute kidney injury in patients with sepsis: a contemporary analysis,” *International Journal of Infectious Diseases*, vol. 13, no. 2, pp. 176–181, 2009.

[36] M. L. Esson and R. W. Schrier, “Diagnosis and treatment of acute tubular necrosis,” *Annals of Internal Medicine*, vol. 137, no. 9, pp. 744–752, 2002.

[37] D. Payen, A. C. de Pont, Y. Sakr, C. Spies, K. Reinbart, and J. L. Vincent, “A positive fluid balance is associated with a worse outcome in patients with acute renal failure,” *Critical Care*, vol. 12, no. 3, article R74, 2008.
P. M. Honore, R. Jacobs, O. Joannes-Boyau et al., “Septic AKI in ICU patients. Diagnosis, pathophysiology, and treatment type, dosing, and timing: a comprehensive review of recent and future developments,” *Annals of Intensive Care*, vol. 1, p. 32, 2011.

V. F. Seabra, E. M. Balk, O. Liangos, M. A. Sosa, M. Cendoroglo, and B. L. Jaber, “Timing of renal replacement therapy initiation in acute renal failure: a meta-analysis,” *American Journal of Kidney Diseases*, vol. 52, no. 2, pp. 272–284, 2008.

R. Bellomo, C. Ronco, J. A. Kellum, R. L. Mehta, and P. Palevsky, “Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group,” *Critical Care*, vol. 8, no. 4, pp. R204–R212, 2004.

R. L. Mehta, J. A. Kellum, S. V. Shah et al., “Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury,” *Critical Care*, vol. 11, no. 2, article R31, 2007.

N. Y. Abosaif, Y. A. Tolba, M. Heap, J. Russell, and A. M. El Nahas, “The outcome of acute renal failure in the intensive care unit according to RIFLE: model application, sensitivity, and predictability,” *American Journal of Kidney Diseases*, vol. 46, no. 6, pp. 1038–1048, 2005.

Z. Ricci, D. Cruz, and C. Ronco, “The RIFLE criteria and mortality in acute kidney injury: a systematic review,” *Kidney International*, vol. 73, no. 5, pp. 538–546, 2008.

A. Kuitunen, A. Vento, R. Suojaranta-Ylinen, and V. Pettilä, “Acute renal failure after cardiac surgery: evaluation of the RIFLE classification,” *Annals of Thoracic Surgery*, vol. 81, no. 2, pp. 542–546, 2006.

F. B. Rodrigues, R. G. Bruetto, U. S. Torres, A. P. Otaviano, D. M. T. Zanetta, and E. A. Burdmann, “Incidence and mortality of acute kidney injury after myocardial infarction: a comparison between KDIGO and RIFLE criteria,” *PLoS ONE*, vol. 8, no. 7, Article ID e69998, 2013.

A. K. Roy, C. Mc Gorrian, C. Treacy et al., “A comparison of traditional and novel definitions (RIFLE, AKIN, and KDIGO) of acute kidney injury for the prediction of outcomes in acute decompensated heart failure,” *Cardiorenal Medicine*, vol. 3, no. 1, pp. 26–37, 2013.

E. Rivers, B. Nguyen, S. Havstad et al., “Early goal-directed therapy in the treatment of severe sepsis and septic shock,” *The New England Journal of Medicine*, vol. 345, no. 19, pp. 1368–1377, 2001.

C. Guerin, R. Girard, J. M. Selli, J. P. Perdrix, and L. Ayzac, “Initial versus delayed acute renal failure in the intensive care unit: a multicenter prospective epidemiological study,” *American Journal of Respiratory and Critical Care Medicine*, vol. 161, no. 3, pp. 872–879, 2000.

J. A. Lopes, S. Jorge, C. Santos et al., “Acute kidney injury in patients with sepsis: a contemporary analysis,” *International Journal of Infectious Diseases*, vol. 13, pp. 176–181, 2009.